King of Prussia, Pennsylvania -- Biotechnology company Genomind raised an additional $2.2 million in equity venture capital funding, according to an SEC regulatory filing.
Genomind is developing genetic testing technologies that it believes will bring innovation to mental healthcare.
Investors in the additional financing were not disclosed, nor was how the company intends to use the funding proceeds.
A total of six investors have participated in the offering to-date.
Genomind is still seeking $2 million in additional equity funding, according to the filing.
Minimum investment size per investor is listed as $200,000.